Key facts
- Notable investors include Frees Fund.
- Status: Privately Held (backing).
Investors
1- ·The complete investor list — 1 names
- ·Watchlist + deal alerts for Anranfei (Kunshan) New Drug Research and Development
- ·The full record, as it builds
Funding rounds
No funding rounds for Anranfei (Kunshan) New Drug Research and Development are on record yet — either the company hasn't raised institutional capital, or the raise hasn't surfaced in our sources.
About Anranfei (Kunshan) New Drug Research and Development
Operator of a biopharmaceutical startup intended to focus on research and development of innovative drugs that can regulate the secretion of neurotransmitters. The company offers cutting-edge laboratory technologies, comprehensive preclinical testing services, molecular modeling, and regulatory support, enabling pharmaceutical and biotechnology organizations to accelerate drug development timelines and enhance efficacy and safety profiles of new medications.
- Sector
- Healthcare
- HQ
- Kunshan, China
- Founded
- 2023
- Ownership
- Privately Held (backing)
Anranfei (Kunshan) New Drug Research and Development doesn't have a composite mark yet — a PA Mark is published once enough pricing inputs exist (trade prints, fund marks, round prices). The rest of the record below builds toward it.
Recorded secondary trades
No secondary trades in Anranfei (Kunshan) New Drug Research and Development shares have been recorded yet. When a print lands — third-party, direct report, or platform — it appears here with structure, source, and price.
Institutional fund marks
No SEC-registered fund has reported a fair-value mark on Anranfei (Kunshan) New Drug Research and Development in its N-PORT filings yet. We sweep new filings monthly.